GeneralConnection.com ➔ Dictionary
Dictionary Search

degrader

Synonyms

Noun

1. debaser

2. person, individual, someone, somebody, mortal, human, soul

Usage
Roche bets $700M upfront on Nurix’s late-phase BTK degrader to tee up Lilly showdown - Fierce Biotech
Roche to co-develop BTK degrader bexobrutideg with Nurix in $2.3B deal - The Clinical Trial Vanguard
Roche inks $2.3B deal with Nurix for BTK degrader - FirstWord Pharma
Nurix to work with Roche on BTK degrader in pact worth up to $2.3B - Endpoints News
Roche And Nurix Therapeutics: Up To $2.3 Billion Collaboration For BTK Degrader Bexobrutideg - Pulse 2.0
Cancer fight: Roche agrees $700M upfront for BTK degrader bexobrutideg - Stock Titan
Roche To Collaborate With Nurix Therapeutics On BTK Degrader Bexobrutideg - TradingView
Roche announces global collaboration with Nurix - GlobeNewswire
Amphista’s AMX-883 BRD9 degrader wins FDA IND clearance for AML - The Clinical Trial Vanguard
Roche, Nurix Therapeutics to Develop, Commercialize BTK Degrader Bexobrutideg - marketscreener.com
Amphista Therapeutics announces FDA clearance of IND application for AMX-883, its lead Targeted Glue™ degrader for acute myeloid leukaemia - The Manila Times
Nurix (NASDAQ: NRIX) lands $700M Roche bexobrutideg pact with up to $2.3B - Stock Titan
Activity of PROTAC MDM2 degrader in primary leukemia cells and PDX models - Nature
First-in-Class Investigational Drug KRAS G12D Degrader Shows Promise in Lung and Pancreatic Cancers - Memorial Sloan Kettering Cancer Center
Nurix Therapeutics Announces Global Collaboration with Roche to Co-Develop and Co-Commercialize Potential Best-in-Class BTK Degrader Bexobrutideg Across Malignant Hematology, Immunology and Neurology - The Manila Times
A dihydrouracil CRBN ligand mitigates IMiD associated safety liabilities in heterobifunctional targeted protein degrader - Nature
ARVN: First PROTAC degrader approved; pipeline prioritization and key milestones drive focus - TradingView
Roche teams with Nurix on pill for blood cancers, MS and hives in $2.3B pact - Stock Titan
A STAT3 degrader demonstrates efficacy in venetoclax resistant acute myeloid leukemia - Nature
A degrader of HER2 and EGFR abolishes p95HER2 and shows robust antitumor efficacy in HER2-positive breast cancer - Nature
NRIX: BTK degrader advances in CLL with strong data, new trials, and broad pipeline momentum - TradingView
Biologic degraders push forward in the clinic - Nature
Pinetree Therapeutics Announces Exercise of Option to License EGFR Degrader Program by AstraZeneca - PR Newswire
Development of a targeted BioPROTAC degrader selective for misfolded SOD1 - Nature
Gilead pays Kymera $45M to glue preclinical protein degrader onto burgeoning oncology pipeline - Fierce Biotech
C4 ditches its EGFR degrader | ApexOnco - Clinical Trials news and analysis - Oncology Pipeline
Discovery of a CNS active GSK3 degrader using orthogonally reactive linker screening - Nature
Blood–Brain Barrier (BBB)-Penetrable Androgen Receptor (AR) Degrader as a Potential Therapeutic Agent for Glioblastoma - ACS Publications
Discovery of a novel small molecule degrader of wild type and mutant estrogen receptors using DNA encoded libraries - Nature
A targeted protein degrader that doubles as a cancer vaccine - Chemical & Engineering News
Molecular Glue Degrader TRI-611 Receives FDA Fast Track for ALK+ NSCLC - Medical Professionals Reference
AstraZeneca plucks preclinical EGFR degrader from Pinetree for $25M - Fierce Biotech
A rapid imaging-based screen for induced-proximity degraders identifies a potent degrader of oncoprotein SKP2 - Nature
Degron Therapeutics Closes $40 Million Series A Extension to Support Molecular Glue Degrader Clinical Development - Business Wire
Roche and C4 Therapeutics to advance degrader-antibody conjugates research - Pharmaceutical Technology
A selective RPL15 PROTAC degrader enhances anti-PD-1 immunotherapy in a murine melanoma tumor model - Nature
Arvinas Joins Michael J. Fox Foundation LRRK2 Consortium to Advance Protein Degrader Research - geneonline.com
The intriguing world of protein degraders - Nature
Phase 1/2 trial launches of molecular glue degrader for ccRCC - Urology Times
Arvinas Sharpens Pipeline Focus After First PROTAC Approval, Eyes Key Trial Data - TradingView
Fledgling French biotech pens $128M deal for Kezar's preclinical protein degrader program - Fierce Biotech
Biohaven Highlights Portfolio Progress, Positive Early Patient Data from Priority Degrader Programs and Anticipated Milestones at the 44th Annual J.P. Morgan Healthcare Conference - PR Newswire
Discovery of a Potent and Selective TEAD Degrader with Durable Degradation Activity - Wiley
RBM39 degrader invigorates innate immunity to eradicate neuroblastoma despite cancer cell plasticity - Nature
Orum pulls in $100M to fund degrader-antibody conjugate pipeline - FirstWord Pharma
Discovery of KRAS(G12D) selective degrader ASP3082 - Nature
Degrader-antibody conjugates move past a rocky debut - biocentury.com
New E3 ligase atlas aims to expand degrader drug discovery - BioWorld News
Kymera Launches Parallel Phase 2b Trials for STAT6 Degrader KT-621 - The Clinical Trial Vanguard
FDA accepts BMS protein degrader for review; Disc rare disease drug rejected - BioPharma Dive
Roche places a $1bn bet on C4T degrader-antibody conjugates - pharmaphorum
Roche Explores Degrader Antibody Conjugates To Support Oncology Pipeline - Yahoo Finance
2025 Michael Ferro – PCF Young Investigator Award - Prostate Cancer Foundation (PCF)
Harnessing artificial intelligence to identify Bufalin as a molecular glue degrader of estrogen receptor alpha - Nature
Arvinas and Pfizer seek a new home for protein degrader drug - Chemistry World
First Volunteer Dosed in Innocare’s New VAV1 Degrader Trial - The Clinical Trial Vanguard
Kymera's Oral STAT6 Degrader KT-621 Shows Biologic-Like Activity in Early Atopic Dermatitis Trial - Patient Care Online
Biotheryx Announces Data from its Phase 1 Dose Escalation Study of BTX-9341, a First-in-Class, Potent and Selective CDK4/6 Degrader, for the Treatment of Advanced/Metastatic HR+/HER2- Breast Cancer - PR Newswire
Degron Therapeutics Closes $40M Series A Extension Advancing Molecular Glue Degrader - Contract Pharma
AI builds dual-action cancer drug targeting PKMYT1 - Drug Target Review
Kymera Advances STAT6 Degrader KT-621 in Phase 2b Atopic Dermatitis, Asthma Trials - The Clinical Trial Vanguard
Pfizer-backed Triana scores $120M series B to take molecular glue degrader into clinic - Fierce Biotech
When ADCs meet targeted protein degraders: The emerging field of degrader-antibody conjugates - Labiotech.eu
PAQ Therapeutics Announces Series B Extension, Bringing Total Series B Financing to $77 Million; First Patient Dosed in Phase 1 Trial of PT0511, a Pan-KRAS Degrader - PR Newswire
Nurix trims workforce as pivotal trial for lead BTK degrader kicks off - Fierce Biotech
EpiBiologics Advances Tissue Selective EGFR Degrader EPI 326 Into First In Human Clinical Study - BioPharma APAC
Neomorph secures $100M Series B to scale molecular glue degrader pipeline - The Pharma Letter
Developing a CITK protein degrader using the QuicTPD™ platform - Chemistry World
Kymera’s IRF5 degrader shows potential in IBD treatment - BioWorld News
Roche, C4 deepen alliance with bet on degrader-antibody hybrid modality - FirstWord Pharma
ESMO 2025: Phase 1 Study of QLH12016, an Androgen Receptor PROTAC Degrader in Heavily Pretreated Patients with mCRPC: Safety, Tolerability, and Antitumor Activity - UroToday
Transcriptomic and epigenetic profiling of neuroblastoma states in response to RBM39 degrader - Nature
Degrader Therapy Tests Efficacy Against Advanced Prostate Cancer in Preclinical Studies - Jie Luo - UroToday
FTO degrader impairs ribosome biogenesis and protein translation in acute myeloid leukemia - Science | AAAS
Accelerating protein degrader discovery with the direct-to-biology workflow - News-Medical
AffyXell, ProAbTech team up on LYTAC protein degrader therapies for autoimmune diseases - koreabiomed.com
Novel PROTAC degrader targeting SAMHD1 disclosed - BioWorld News
SEED Therapeutics Reports Tumor Eradication in a - GlobeNewswire
New SMARCA2 degrader for SMARCA4-deficient cancers described - BioWorld News
Mode of action of a DCAF16-recruiting targeted glue that can selectively degrade BRD9 - Nature
Gilead and Roche Bet on Protein Degraders for Their Cancer Drug Pipelines - MedCity News
One to Watch: Kymera Therapeutics Oral STAT6 Degrader Fast-Tracked by U.S. FDA for AD - The Dermatology Digest
Former Genentech leaders’ protein degrader startup nets $107M - Endpoints News
Protein degraders gain speed as Arvinas scores landmark approval - Pharma Voice
Amgen buys protein-degrading startup Dark Blue for up to $840M - BioPharma Dive
6 Biotechs Targeting the Undruggable with Precision - Clarivate
KT-621 Shows Strong Phase 1 Results as First-in-Class Oral STAT6 Degrader - Dermatology Times
Targeted Protein Degradation and Novel Modalities: Getting on the Frontline - Fierce Pharma
Jiangsu Hengrui Pharmaceuticals Co. discovers new CDK7 degrader PROTACs - BioWorld News
Nurix: 'Strong Buy' Bexobruditeg Development And Dual Degrader Zelebrudomide (NASDAQ:NRIX) - Seeking Alpha
PROTAC Degrader Targeting HDAC4 Enhances Radiation Therapy Effectiveness in Lung Cancer Treatment - geneonline.com
Genexine’s First-in-Class SOX2 Degrader GX-BP1 Demonstrates Up to 96% TGI and Eliminates Tumor Regrowth in Preclinical Models - BioSpace
Foghorn Therapeutics to Present New Preclinical Data for Selective SMARCA2 Inhibitor FHD-909 and Selective CBP, EP300 and ARID1B Degrader Programs at the 2026 AACR Annual Meeting - GlobeNewswire
Innocare IND Approval For New VAV1 Degrader Trial In China - The Clinical Trial Vanguard
SEED Therapeutics to Present Phase 1 Trial Design for - GlobeNewswire
Did Nurix’s (NRIX) EHA Oral BTK Degrader Data Just Reframe Its Oncology Investment Narrative? - simplywall.st
Orum Therapeutics Presents New Preclinical Data at AACR 2026 on ORM-1153, a CD123-Targeting Degrader-Antibody Conjugate, Highlighting Broad Activity in Acute Myeloid Leukemia and the Potential for Improved Efficacy and Tolerability - BioSpace
Prelude Therapeutics Presents Preclinical Data from Development Candidate, PRT13722, a First-in-Class, Orally Bioavailable, Potent and Highly Selective KAT6A Degrader at American Association for Cancer Research (AACR) Annual Meeting 2026 - GlobeNewswire
Eilean Therapeutics Presents First-in-Class MALT1 Degrader TE205 Demonstrating In Vivo Efficacy in Ulcerative Colitis at the 4th International Conference on Microbiology and Immunology - PR Newswire
Atopic dermatitis data bolster Kymera's hopes of matching Dupixent's efficacy with oral STAT6 degrader - FirstWord Pharma
Foreign Language Equivalents
Foreign Language Equivalents of 'degrader'
Language Equivalent   Language Equivalent
French    Spanish
Misspellings - Typos
degraderr,   degrdaer,   degrder,   degeader,   degrafer,   degraser,   derader,   egrader,   edgrader,   degradrr,   defrader,   degraedr,   degrrader,   dwgrader,   degraer,   deegrader,   dgrader,   dergader,   drgrader,   fegrader,   degradeer,   degrador,   dgerader,   ddegrader,   degradre,   degader,   degrsder,   deggrader,   degradder,   degraader,   degradee,   degtader,   degradwr,   degradr,   degarder,   degradet,   dehrader,   segrader,   degrade
Words Starting with Letter - 'A'
a a battery a billion
a bit a bit much a capella singing
a cappella singing a couple of a few
a fortiori a good deal a great deal
a horizon a hundred a hundred and one
a hundred thousand a hundred times a kempis
a la carte a la mode a level
a little a lot a million
Go to Page 1              Go to Page 2 »   
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z